Thyrocare Technologies Ltd

Thyrocare Technologies Ltd

$THYROCAREHealthcare Service ProviderNSEBSE

Thyrocare Technologies Ltd (THYROCARE) last traded at ₹598, a market capitalisation of ₹9,521 crore, on a P/E of 52.7. Over the past 52 weeks the stock has ranged between ₹343 and ₹662. Thyrocare Technologies Ltd last reported results for the quarter ended Jun 2026, with sales of ₹240 crore and net profit of ₹51 crore. Figures are as of 25 Aug 2026 and are not real time.

Thyrocare Technologies Ltd share price and key metrics

Current price
₹598
Market cap
₹9,521 cr
Stock P/E
52.7
Book value
₹36.8
ROE
28.4%
ROCE
35.4%
Dividend yield
1.57%
52w high / low
662/343

Metrics as of 25 Aug 2026. Not real time.

Thyrocare Technologies Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹240 cr, up 24.4% from ₹193 cr a year earlier. Net profit was ₹51 cr, up 34.2% year on year.

Thyrocare Technologies Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales177166187193217196224240
Expenses129124130135145138149163
Operating profit4842575871587577
OPM %27%25%30%30%33%30%34%32%
Other income34553-155
Interest11111-021
Depreciation1317141112221412
Profit before tax3728475063356468
Tax %28%32%54%24%24%21%24%25%
Net profit2619223848284951
EPS (₹)1.681.201.362.453.021.822.963.28

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Thyrocare Technologies Ltd annual results

Thyrocare Technologies Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales495589527572687829876
Operating profit171236123140190263282
OPM %35%40%23%24%28%32%32%
Net profit113176646991163176
EPS (₹)7.1311.104.064.455.7610.2411.08

TTM is the trailing twelve months to the most recent quarter.

Thyrocare Technologies Ltd growth and returns

Compounded Sales Growth
10 Years
13%
5 Years
11%
3 Years
16%
TTM
21%
Compounded Profit Growth
10 Years
12%
5 Years
8%
3 Years
36%
TTM
70%
Stock Price CAGR
10 Years
12%
5 Years
7%
3 Years
48%
1 Year
38%
Return on Equity
10 Years
21%
5 Years
20%
3 Years
20%
Last Year
28%

Thyrocare Technologies Ltd shareholding pattern

Promoters held 60.92% at Jun 2026, down from 71.06% at Jun 2025. FIIs 5.43% and DIIs 20.92%.

Thyrocare Technologies Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters71.11%71.06%71.06%71.06%71.06%60.93%60.92%60.92%
FIIs1.93%2.77%2.41%3.23%4.85%4.96%5.37%5.43%
DIIs14.79%14.68%14.97%14.54%13.47%20.52%21.00%20.92%
Public12.15%11.49%11.57%11.18%10.61%13.61%12.71%12.71%
No. of shareholders59,37756,66657,40354,56654,14277,61973,37773,064

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Thyrocare Technologies Ltd corporate filings

  • Disclosure under Regulation 30A of LODROtherslow impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies has announced the complete discharge and release of transaction…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship LtdInsider Trading / SASThigh impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies Limited has announced the complete release of a pledge on 7 crore…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PACsInsider Trading / SASTmedium impact
    Filing PDF

    Cruxal's analysis: Docon Technologies Private Limited, the promoter of Thyrocare Technologies Limited, has…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt LtdInsider Trading / SASThigh impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies Limited has announced that its promoter, Docon Technologies…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HSBC Mutual FundInsider Trading / SASTmedium impact
    Filing PDF

    Cruxal's analysis: HSBC Mutual Fund has disclosed an acquisition of 29.99 lakh shares of Thyrocare…

    Read the full analysis
  • The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 13, 2026 for Docon Technologies Pvt LtdInsider Trading / SASTmedium impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies Limited's promoter, Docon Technologies Private Limited, has…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PACInsider Trading / SASThigh impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies Limited's promoter, Docon Technologies Private Limited, has…

    Read the full analysis
  • The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 17, 2026 for Docon Technologies Pvt LtdInsider Trading / SASThigh impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies Limited's promoter, Docon Technologies Private Limited, has…

    Read the full analysis
  • Communication Received From Promoter Regarding Release Of Pledge On Equity Shares Of Thyrocare Technologies LimitedCompany Updatemedium impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies has received an intimation from its promoter regarding the release…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual FundInsider Trading / SASTlow impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies Ltd. has seen a reduction in shareholding by ICICI Prudential…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship LtdInsider Trading / SASTmedium impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies Limited has announced the release of a pledge on 1.75 crore equity…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt LtdInsider Trading / SASThigh impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies Limited promoter, Docon Technologies Private Limited, has sold 1…

    Read the full analysis
  • The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PACsInsider Trading / SASTmedium impact
    Filing PDF

    Cruxal's analysis: Docon Technologies Private Limited, the promoter of Thyrocare Technologies Limited, has…

    Read the full analysis
  • Communication Received From Promoter Regarding Sale Of 1,57,69,696 Equity Shares Of The Company By Promoter - Docon Technologies Private Limited.Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Thyrocare Technologies Limited has disclosed that its promoter, Docon Technologies…

    Read the full analysis
  • Please find the attached disclosure received from Docon Technologies Private Limited ("Promoter") for release of pledge on equity shares of the CompanyCompany Updatemedium impact
    Filing PDF

    Cruxal's analysis: Docon Technologies Private Limited, a promoter of Thyrocare Technologies Ltd, has…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Thyrocare Technologies Ltd

Cruxal reads every Thyrocare Technologies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Thyrocare Technologies Ltd (THYROCARE) Results, Financials & Share Price | Cruxal